CN Patent

CN114716436A — Kras g12c突变抑制剂及其用途

Assigned to Guangzhou Baiting Medicine Technology Co ltd · Expires 2022-07-08 · 4y expired

What this patent protects

本发明公开了抑制KRAS G12C突变的化合物，所述化合物药学上可接受的盐、光学异构体、活性代谢物和前药，以及含有所述化合物或其盐的药物组合物在治疗KRAS G12C突变引起的肿瘤等增殖性疾病中的用途。

USPTO Abstract

本发明公开了抑制KRAS G12C突变的化合物，所述化合物药学上可接受的盐、光学异构体、活性代谢物和前药，以及含有所述化合物或其盐的药物组合物在治疗KRAS G12C突变引起的肿瘤等增殖性疾病中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN114716436A
Jurisdiction
CN
Classification
—
Expires
2022-07-08
Drug substance claim
No
Drug product claim
No
Assignee
Guangzhou Baiting Medicine Technology Co ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.